Across TCGA pan-cancer cohorts, PLXNB3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PLXNB3 data layer compared with 26 for mass-spec protein and 13 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PLXNB3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLXNB3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, GBM, and LSCC are the cancer types where PLXNB3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.966	0.539	.033	8	view →
GBM	OS	Quartile	All	0.303	0.724	.008	7	view →
LSCC	DFS	Tertile	All	0.659	0.933	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PLXNB3 tumor-vs-normal RNA expression · all PLXNB3 data types